U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
HOUSTON, April 26, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3 at 2:10 p.m. EDT in Boston, Massachusetts.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
